Everything below concerns reconstitution. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-03. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Several ribosomopathies share features such as inherited bone marrow failure, which is characterized a reduced number of blood cells and by a predisposition to cancer. Other features can include skeletal abnormalities and growth retardation. However, clinically these diseases are distinct, and do not show a consistent set of features.
=== Early work === Following the completion of his formal education, Stein became a researcher under Bergmann at Rockefeller Institute, where much of his most important work was done. Stanford Moore joined Bergmann's lab in 1939, where he and Stein began research focusing on amino acids. According to Moore, "During the early years of our cooperation, Stein and I worked out a system of collaboration that lasted for a lifetime." Their work in this area was disrupted with the beginning of World War II, and they temporarily parted ways to aid the war efforts, Stein staying with Bergmann to research the molecular scale effect of blister agents on the human body. They began collaborating again, however, after Bergmann died in 1944 and they were given an opportunity by the Director of the Rockefeller Institute, Herbert S. Gasser, to continue Bergmann's work in amino acids.
Mummification is one of the defining customs in ancient Egyptian society for people today. The practice of preserving the human body is believed to be a quintessential feature of Egyptian life. Yet even mummification has a history of development and was accessible to different ranks of society in different ways during different periods. There were at least three different processes of mummification according to Herodotus. They range from "the most perfect" to the method employed by the "poorer classes".
Sources: en.wikipedia.org
Bukele announced at the Bitcoin 2021 conference on 5 June 2021 that he would introduce a bill to the Legislative Assembly that would make bitcoin legal tender, saying that it would "generate jobs" and promote "financial inclusion" in the short term. The Legislative Assembly approved the bill three days later. Although the World Bank rejected a request from the Salvadoran government to assist it with the implementation of bitcoin as legal tender, citing concerns about transparency and the environmental effects of bitcoin mining, Athena Bitcoin announced that it would invest $1 million to install 1,500 bitcoin ATMs. This would allow users to exchange U.S. dollars for bitcoin and vice versa. Bitcoin became legal tender on 7 September 2021 in El Salvador, the first country to do so. It became legal tender alongside the United States dollar, which had been adopted in 2001 and replaced the Salvadoran colón. About 1,000 people marched in the streets of San Salvador to protest the country's adoption of bitcoin, though other citizens saw the adoption as an "opportunity." According to The New York Times, bitcoin adoption has allowed Salvadorans without bank accounts to "access digital payments, invest savings or boost earnings." The day before bitcoin became legal tender, Bukele announced that the Salvadoran government had bought its first 200 bitcoins. Economist Steve Hanke stated that El Salvador had "the most distressed sovereign debt in the world" due to its adoption of bitcoin, and other economists predicted that the country would likely default on its debt.
A total solar eclipse occurs at the Moon's descending node of the orbit in North America and Europe. The total eclipse passes over the Arctic, Greenland, Iceland, the Atlantic Ocean and northern Spain. Trump announces that White House Press Secretary Karoline Leavitt will leave the office at the end of the month to spend more time with her family. 2026 Iran war: US media reports that sailors on the Abraham Lincoln attempted to jump overboard owing to poor conditions such as food shortages, a mental health crisis, and broken toilets that affected all crew members, including female soldiers. Pete Hegseth, the US secretary of defense, denounces the sailors as liars. The US eventually opts to send the aircraft carrier USS George Washington to the Middle East to replace the Lincoln, removing its last aircraft carrier in the Pacific. August 13 – The United States sees the first triple execution on the same day, since 2010. August 14 Six people are killed, including the perpetrator, and one person is injured in a mass shooting at three different locations in Missaukee County, Michigan. Trump announces that the US will annex the Strait of Hormuz "pretty soon" after defeating the Iranian regime in the war. 2026 NFL season: The National Football League suspends Atlanta Falcons linebacker James Pearce Jr. for eight games in violation of the league's personal conduct policy after his arrest in February on domestic violence charges. August 15 – The Democratic National Committee votes to approve South Carolina as the first U.S.
== Nuclear energy applications == In a fission nuclear reactor, uranium-238 can be used to generate plutonium-239, which itself can be used in a nuclear weapon or as a nuclear-reactor fuel supply. In a typical nuclear reactor, up to one-third of the generated power comes from the fission of 239Pu, which is not supplied as a fuel to the reactor, but rather, produced from 238U. A certain amount of production of 239Pu from 238U is unavoidable wherever it is exposed to neutron radiation. Depending on burnup and neutron temperature, different shares of the 239Pu are converted to 240Pu, which determines the "grade" of produced plutonium, ranging from weapons grade, through reactor grade, to plutonium so high in 240Pu that it cannot be used in current reactors operating with a thermal neutron spectrum. The latter usually involves used "recycled" MOX fuel which entered the reactor containing significant amounts of plutonium.
=== Phase III ACHIEVE-1 trial === In April 2025, results from a phase III clinical trial involving 559 people with type 2 diabetes who took an oral orforglipron pill or a placebo daily for 40 weeks showed that orforglipron produced a reduction of hemoglobin A1C level by 1.3 to 1.6 percentage points from a starting level of 8%. More than 65% of participants taking the highest dose of orforglipron achieved a reduction of hemoglobin A1C level by more than or equal to 1.5 percentage points, bringing them into the non-diabetic range as defined by the American Diabetes Association. People taking the highest dose of the pill lost 8% of their weight, or around 16 lb (7.3 kg), on average after 40 weeks. In its press release, Lilly noted that the subjects' weight loss had not yet plateaued at the time the trial concluded, and suggested that this indicated that greater weight reduction would ultimately be achieved with extended therapy. Side effects were similar to those seen with other GLP-1 agonists, and no significant liver problems were observed.
Sources: en.wikipedia.org
The concentrations of species containing reagent A are constrained by a condition of mass-balance, that is, the total (or analytical) concentration, which is the sum of all species' concentrations, must be constant. There is one mass-balance equation for each reagent of the type
==== Schizophrenia ==== People diagnosed with schizophrenia tend to have lower serum vitamin D concentrations compared to those without the condition. This may be a consequence of the disease rather than a cause, due, for example, to low dietary vitamin D and less time spent exposed to sunlight. Results from supplementation trials have been inconclusive.
There are two dedicated Noma hospitals in Nigeria, the first and oldest of which is the Noma Children Hospital Sokoto, staffed by resident and visiting medical teams supported by Médecins Sans Frontières. Some of the staff are noma survivors. The second and more recently commissioned centre is the Noma Centre Abuja, fully funded and sponsored by the Noma Aid Nigeria Initiative, where holistic and compressive management of the Noma patients is given. The team consists of a resident medical and surgical team and visiting surgeons from Europe. In other countries, such as Ethiopia, international charities work in collaboration with the local health care system to provide complex reconstructive surgery which can give back facial functions such as eating, speaking, and smiling. Teams of volunteer medics coming from abroad are often needed to support the local capacity to address the most severe cases, which can be extremely challenging even for senior maxillofacial surgeons. On 10 June 2010, the work of such volunteer surgeons was featured in a UK BBC Two documentary presented by Ben Fogle, Make Me a New Face: Hope for Africa's Hidden Children.
Development, implementation, analysis and reporting Leading quality improvement initiatives based on audit findings. An example from the UK is the National Comparative Audit of Blood Transfusion (NCABT), which is a programme of clinical audits that look at the use and administration of blood and blood components in the National Health System (NHS) and independent hospitals in the UK. This audit programme's objectives are to provide evidence that blood is being prescribed and used appropriately and administered safely. It also highlights where practice is deviating from the guidelines and how this might affect patient outcomes. Data collection for these audits can be undertaken by a variety of health care professionals within the participating organisations, however the majority of the data collection and data submission is undertaken by the TP.
==== Exfoliation with supercritical carbon dioxide ==== Liquid-phase exfoliation can also be done by a less-known process of intercalating supercritical carbon dioxide (scCO2) into the interstitial spaces in the graphite lattice, followed by rapid depressurization. The scCO2 intercalates easily inside the graphite lattice at a pressure of roughly 100 atm. Carbon dioxide turns gaseous as soon as the vessel is depressurized and makes the graphite explode into few-layered graphene. This method may have multiple advantages: being non-toxic, the graphite does not have to be chemically treated in any way before the process, and the whole process can be completed in a single step as opposed to other exfoliation methods.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.